ArticleScientific reports2026
Selective removal of soluble FLT-1 using a high-affinity DNA aptamer for potential apheresis treatment of preeclampsia.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preeclampsia (PE) is a pregnancy-specific hypertensive disorder that has been associated with elevated levels of soluble fms-like tyrosine kinase-1 (sFLT-1), which is thought to contribute to impaired angiogenesis by binding and neutralizing angiogenic factors such as Vascular Endothelial Growth Factor (VEGF) and Placental Growth Factor (PlGF). Selective removal of sFLT-1 from the maternal circulation is being explored as a potential therapeutic approach for PE. In this study, we developed TXB-0080, a high-affinity DNA aptamer containing two distinct artificial bases (Xenoligo platform), which binds sFLT-1 with an affinity of KD = 0.084 ± 0.023 nM. TXB-0080 was immobilized onto Sepharose beads to construct an apheresis model that efficiently and specifically removed sFLT-1 from serum. The aptamer-conjugated beads exhibited stability against autoclaving and compatibility with clinical anticoagulants. Notably, it did not bind free PlGF but effectively captured sFLT-1 without interfering with its interaction with ligands. These findings support the feasibility of aptamer-based apheresis as a novel and targeted strategy to address sFLT-1–associated pathology in PE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.